1. Erwig LP，Rees AJ.Rapidly progressive glomerulonephritis. J.Nephrol，1999，12 Suppl 2：S111-S119.

2. Couser WG.Rapidly progressive glomerulonephritis：classification，pathogenetic mechanisms，and therapy.Am J Kidney Dis，1988，11：449-464.

3.陈惠萍，曾彩虹，胡伟新，等.10594例肾活检病理资料分析.肾脏病与透析肾移植杂志，2000，9（6）：501-509.

4. ZhouFD，Zhao MH，Zou WZ，et al.The changing spectrum of primary glomerular diseases within 15 years：A survey of 3331 patients in a single Chinese centre. Nephrol Dial Transplant，2009，24（3）：870-876.

5. Cui Z，Zhao J，Jia XY，et al. Anti-glomerular basement membrane disease：outcomes of different therapeutic regimens in a large single-center Chinese cohort study.Medicine（Baltimore），2011，90（5）：303-311.

6. Zhou XJ，Lv JC，Zhao MH，et al.Advances in the genetics of anti-glomerular basement membrane disease. Am J Nephrol，2010，32：482-490.

7. Jennette JC，Nickeleit V.Anti-glomerular basement membrane glomerulonephritis and Goodpature’s syndrome// Jennette JC，ed.Heptinstall’s pathology of the kidney.4th ed.Philadelphia：Lippincott Willianms and Wilkin.2007：613-641.

8. Nacheman PH，Jennette JC，Falk RJ.Primary glomerular disease//Taal MW，Chertow GM，Marsden PA，et al.Brenner and Rector’s The Kidney.9th ed.Philadelphia：Saunders，2012：1153-1168.

9. Tarzi RM1，Cook HT，Pusey CD.Crescentic glomerulonephritis：new aspects of pathogenesis.Semin Nephrol，2011，31（4）：361-368.

10. Cui Z1，Zhao MH. Avidity of anti-glomerular basement membrane autoantibodies was associated with disease severity.Clin Immunol，2005，116（1）：77-82.

11. Yang R，Hellmark T，Zhao J，et al.Levels of epitope-specific autoantibodies correlate with renal damage in anti-GBM disease.Nephrol Dial Transplant，2009，24：1838-1844.

12. Cui Z，Wang HY，Zhao MH，et al.Natural autoantibodies against glomerular basement membrane exist in normal human sera.Kidney Int，2006，69：894-899.

13. Olson SW，Arbogast CB，Baker TP，et al.Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. J Am Soc Nephrol，2011，22：1946-1952.

14. Pedchenko V，Bondar O，Fogo AB，et al.Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis.N Engl J Med，2010，363：343-354.

15. ZouJ，Hannier S，Cairns LS，et al. Healthy individuals have Goodpasture autoantigen-reactive T cells.J Am Soc Neprol，2008，19（2）：396-404.

16. Wu J，Hicks J，Borillo J，et al.CD4（+）T cells specific to a glomerular basement membrane antigen mediate glomerulonephritis.J Clin Inves，2002，109（4）：517-524.

17. Zhou XJ1，Lv JC，Zhao MH.Advances in the genetics of anti-glomerular basement membrane disease.Am J Nephrol，2010，32（5）：482-490.

18. Falk RJ，Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.N Engl J Med，1988，318：1651-1657.

19. Jennette JC，Thomas DB.Pauci-immune and antineutrophil cytoplasmic autoantibody-mediated crescent glomerulonephritis//Jennette JC，ed.Heptinstall’s pathology of the kidney.4th ed.Philadelphia：Lippincott Willianms and Wilkin，2007：664-673.

20. Kallenberg CG.Pathogenesis of ANCA-associated vasculitis，an update.Clin Rev Allergy Immunol，2011，41（2）：224-231.

21. Willcocks LC，Lyons PA，Rees AJ，et al.The contribution of genetic variation and infection to the pathogenesis of ANCA-associated systemic vasculitis.Arthritis Res Ther，2010，12（1）：202.

22. Chen M，Yu F，Wang SX，et al.Antineutrophil cytoplasmic autoantibody-negative pauci-immune crescentic glomerulonephritis.J Am Soc Nephrol，2007，18：599-605.

23. Cui Z，Zhao J，Jia XY，et al. Anti-glomerular basement membrane disease：outcomes of different therapeutic regimens in a large single-center Chinese cohort study.Medicine（Baltimore），2011，90（5）：303-311.

24. Hirayama K，Yamagata K，Kobayashi M，et al.Anti-glomerular basement membrane antibody disease in Japan：part of the nationwide rapidly progressive glomerulonephritis survey in Japan.Clin.Exp.Nephrol，2008，12，339-347.

25. Kidney Disease：Improving Global Outcomes（KDIGO）Glomerulonephritis Work Group.KDIGO clinical practice guideline for glomerulonephritis.Kidney Int Suppl，2012，2：139-274.

26. Levy JB，Turner AN，Rees AJ，et al.Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med，2001，134：1033-1042.

27. Jones RB，Tervaert JW，Hauser T，et al.Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.N Engl J Med，2010，363：211-220.

28. Clark WF.Plasma exchange for renal disease：evidence and use 2011.J Clin Apher，2012，27（3）：112-116.

29. Sanchez AP，Ward DM.Therapeutic apheresis for renal disorders.Semin Dial，2012，25（2）：119-131.

30. Silva F，Specks U，Kalra S，et al.Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement-a prospective，open-label pilot trial.Clin J Am Soc Nephrol，2010，5（3）：445-453.

31. Gómez-Puerta JA，Quintana LF，Stone JH，et al.B-cell depleting agents for ANCA vasculitides：a new therapeutic approach.Autoimmun Rev，2012，11（9）：646-652.

32. Henes JC，Kanz L，Koetter I.et al.Rituximab and leflunomide for Wegener’s granulomatosis：a long-term followup.Rheumatol Int，2011，31（3）：425-426.

33. Niiyama S，Amoh Y，Suzuki K，et al.Efficacy of tacrolimus against Churg-Strauss syndrome in a patient with myasthenia gravis.Rheumatol Int，2010，30（6）：847-848.

34. Lapraik C，Watts R，Bacon P，et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.Rheumatology（Oxford），2007，46（10）：1615-1616.